FORMULATION AND EVALUATION OF SOMATOSTATIN ANALOGUE TABLETS
Objective: This study was undertaken with the aim of the formulation and evaluation of hypothalamic hormone somatostatin analogue tablets, which are intended for neuroendocrine tumours treatment.
Methods: Tablets were prepared by using the wet granulation method and evaluated for weight variation, resistance to crushing, friability, disintegration time, content and content uniformity. Stability tests have been performed.
Results: Characteristics of somatostatin analogue cyphetrylin powder have been investigated, and the wet granulation method has been chosen to prepare tablets. Technical pharmaceutical properties of formulations of different compositions and obtained tablets were estimated and the best formulation CF11 has been established with appropriate characteristics: disintegration time less than 15 min, resistance to crushing more than 30 kg·m·s−2, weight variation ˂7.5 %, active substance content closed to the nominal quantity and consistent cyphetrylin distribution in the batch. Performed examinations showed cyphetrylin tablets stability in the long-term study.
Conclusion: Because of somatostatin analogue cyphetrylin powder properties tablets were prepared by the wet granulation method with starch, lactose, povidone, talc, microcrystalline cellulose, calcium stearate and magnesium stearate as excipients. The best formulation including povidone has characteristics corresponding to requirements of European Pharmacopoeia (PhEur) and State Pharmacopoeia of the Russian Federation (PhRu). Examination of cyphetrylin tablets showed its quality and stability within the time of observation–12 mo.
2. Vinik AI, Chaya C. Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin North Am 2016;1:21-48.
3. Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist 2013;5:525-32.
4. Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf 2017;20:1–13.
5. Shprakh ZS, Yartseva IV, Ignateva EV, Smirnova AP, Sushinina LP, Ustinkina SV, et al. Synthesis and chemico-pharmaceutical characteristics of somatostatin analog with antitumor activity. Pharm Chem J 2014;3:159-62.
6. Mohammed GK, Obaidat RM, Assaf S, Khanfar M, Al-taani B. Formulations and technologies in growth hormone delivery. Int J Pharm Pharm Sci 2017;7:1-12.
7. Preet P. Peptides: a new therapeutic approach. Int J Curr Pharm Res 2018;2:29-34.
8. Sanarova EV, Lantsova AV, Mikhaevich EI, Shprakh ZS, Smirnova LI, Yavorskaya NP, et al. The prospect of the creation of a dosage form of domestic analogue of hypothalamic hormone somatostatin in the treatment of hormone-dependent tumors. Russ J Biopharm 2016;2:14-9.
9. Konyaeva OI, Kulbachevskaya NYu, Ermakova NP, Chaley VA, Merkulova IB, Abramova ?V, et al. Pre-clinical toxicological study of analogue of the hypothalamic hormone. Russ J Biother 2018;2:63-70.
10. European Pharmacopoeia 9.0. Strasbourg: Council of Europe; 2017.
11. State Pharmacopoeia of the Russian Federation. 14th ed. Moscow: The Ministry of Health of the Russian Federation; 2018.
12. Tadwee I, Shahi S, Zaheer Z. Preformulation studies using lactose in the development of solid oral dosage form: a graphical representation using SeDeM method. Int J Curr Pharm Res 2017;5:168-72.
13. Lotfy HM, Saleh SS. Recent development in ultraviolet spectrophotometry through the last decade (2006-2016): a review. Int J Pharm Pharm Sci 2016,1:40-56.
14. Shprakh ZS, Ign?tieva ?V, Yartseva IV, Dmitricheva NA, Smirnova LI. Development and validation of cyphetrylin assay in tablets. Russ J Biother 2016;3:55-61.
This work is licensed under a Creative Commons Attribution 4.0 International License.